AACR 2026 现场信号· @ · X·· 2026-04-22评分60
正文 · 原文
Looking through my #aacr26 collection of posters from yesterday. Prelude Tx have a KAT6A degrader (PRT13722) in early development to compete with inhibitors: https://t.co/23zBtCX8Hs
热度 16 · 15 赞 · 0 回复 · 1 转发
会议摘要
5793按 代号 PRT13722 对上
First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved pre-clinical hematological safety profileMonisha Sivakumar, Sarah Pawley, Corey Basch, Jimin Park, Justin Kurian, Anthony Reichelderfer, Yue Zou, Kirsten Gallagher, Miles Cowart, Joy Cote, Alexander Grego, Jessica Burtell, Amy Crossan, Michael Hulse, Anjana Agarwal, Arpita Mondal, Chun Chen, Vijay Devannah, Sina Rezazadeh, Quincy Lewis, Patrick Wen, Ken Ray, Raul Leal, Daniel Porreca, Ganfeng Cao, Neha Bhagwat, Shanthi Ganesan, Stefan Ruepp, Min Wang, Joseph Rager, Koichi Ito, Sandy Geeganage, Andrew Combs, Peggy Scherle, Andrew Buesking, Jack Carter
读摘要原文 →来源：AACR 2026 现场信号 · x.com